6:29 PM
 | 
Nov 05, 2012
 |  BC Extra  |  Clinical News

Dalcetrapib data published

Detailed results from the Phase III dal-OUTCOMES trial to treat coronary heart disease (CHD) showed dalcetrapib from Roche (SIX:ROG; OTCQX:RHHBY) missed the primary endpoint which consisted of a composite of time to first occurrence of CHD death, non-fatal acute myocardial infarction (MI), hospitalization for unstable angina, resuscitated cardiac arrest or stroke. The endpoint occurred in 8.3%...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >